Company Performance - Foghorn Therapeutics Inc. reported a quarterly loss of $0.28 per share, which was better than the Zacks Consensus Estimate of a loss of $0.31, and an improvement from a loss of $0.45 per share a year ago, representing an earnings surprise of +9.68% [1] - The company posted revenues of $7.56 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 0.85%, but showing an increase from year-ago revenues of $6.89 million [2] - Over the last four quarters, Foghorn Therapeutics has surpassed consensus EPS estimates two times, but has not been able to beat consensus revenue estimates [2] Market Outlook - Foghorn Therapeutics shares have increased by approximately 8.9% since the beginning of the year, outperforming the S&P 500's gain of 7.6% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the coming quarter is -$0.31 on revenues of $7.93 million, and for the current fiscal year, it is -$1.27 on revenues of $29.82 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Foghorn Therapeutics belongs, is currently ranked in the bottom 43% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact investor decisions [5]

Marriott International (MAR) came out with quarterly earnings of $2.65 per share, beating the Zacks Consensus Estimate of $2.64 per share. This compares to earnings of $2.5 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +0.38%. A quarter ago, it was expected that this hotel company would post earnings of $2.27 per share when it actually produced earnings of $2.32, delivering a surprise of +2.2%. Empirical research shows a st ...

Core Insights - Life Time Group Holdings, Inc. (LTH) reported quarterly earnings of $0.37 per share, exceeding the Zacks Consensus Estimate of $0.33 per share, and up from $0.25 per share a year ago, representing an earnings surprise of +12.12% [1] - The company achieved revenues of $761.47 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 1.27% and increasing from $667.76 million year-over-year [2] - Life Time Group Holdings shares have increased approximately 29.3% year-to-date, significantly outperforming the S&P 500's gain of 7.6% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.32 on revenues of $769.91 million, and for the current fiscal year, it is $1.32 on revenues of $2.97 billion [7] - The estimate revisions trend for Life Time Group Holdings was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Leisure and Recreation Services industry, to which Life Time Group Holdings belongs, is currently ranked in the bottom 29% of over 250 Zacks industries, suggesting potential challenges ahead [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact investor sentiment [5]

Core Insights - Zebra Technologies (ZBRA) reported quarterly earnings of $3.61 per share, exceeding the Zacks Consensus Estimate of $3.31 per share, and up from $3.18 per share a year ago [1] - The earnings surprise for the quarter was +9.06%, and the company has surpassed consensus EPS estimates in all four of the last quarters [2] - Zebra's revenues for the quarter reached $1.29 billion, surpassing the Zacks Consensus Estimate by 1.17% and increasing from $1.22 billion year-over-year [3] Financial Performance - The company has consistently exceeded consensus revenue estimates over the last four quarters [3] - The current consensus EPS estimate for the upcoming quarter is $3.24, with expected revenues of $1.28 billion, and for the current fiscal year, the EPS estimate is $14.51 on revenues of $5.23 billion [8] Market Position - Zebra shares have underperformed the market, losing about 11.6% since the beginning of the year, while the S&P 500 has gained 7.6% [4] - The Zacks Industry Rank for Manufacturing - Thermal Products is in the top 41% of over 250 Zacks industries, indicating a favorable position within the sector [9] Future Outlook - The earnings outlook and estimate revisions will be crucial for Zebra's stock performance moving forward [5][6] - The current Zacks Rank for Zebra is 3 (Hold), suggesting that the shares are expected to perform in line with the market in the near future [7]

Core Insights - Clear Channel Outdoor (CCO) reported a quarterly loss of $0.04 per share, consistent with the Zacks Consensus Estimate, and an improvement from a loss of $0.06 per share a year ago [1] - The company generated revenues of $402.81 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 0.80%, but down from $558.54 million year-over-year [2] - CCO's stock has declined approximately 19.7% year-to-date, contrasting with the S&P 500's gain of 7.6% [3] Earnings Outlook - The future performance of CCO's stock will largely depend on management's commentary during the earnings call and the earnings outlook [4] - The current consensus EPS estimate for the upcoming quarter is -$0.05 on revenues of $390.4 million, and for the current fiscal year, it is $0.02 on revenues of $1.57 billion [7] Industry Context - The Advertising and Marketing industry, to which CCO belongs, is currently ranked in the top 32% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked using tools like the Zacks Rank [5][6]

Clear Secure (YOU) came out with quarterly earnings of $0.26 per share, beating the Zacks Consensus Estimate of $0.23 per share. This compares to earnings of $0.34 per share a year ago. These figures are adjusted for non- recurring items. This quarterly report represents an earnings surprise of +13.04%. A quarter ago, it was expected that this airport security company would post earnings of $0.3 per share when it actually produced earnings of $0.32, delivering a surprise of +6.67%. Over the last four quarte ...

分组1 - Offerpad Solutions Inc. reported a quarterly loss of $0.4 per share, slightly worse than the Zacks Consensus Estimate of a loss of $0.39, but an improvement from a loss of $0.5 per share a year ago [1] - The company posted revenues of $160.32 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 10.78% and down from $251.12 million year-over-year [2] - Offerpad Solutions shares have declined approximately 57.2% since the beginning of the year, contrasting with the S&P 500's gain of 6.1% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is -$0.30 on revenues of $229.65 million, and for the current fiscal year, it is -$1.52 on revenues of $806.75 million [7] - The Zacks Industry Rank for Real Estate - Operations is in the top 32% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]

Group 1: Earnings Performance - CRISPR Therapeutics reported a quarterly loss of $1.29 per share, better than the Zacks Consensus Estimate of a loss of $1.47, and an improvement from a loss of $1.49 per share a year ago, representing an earnings surprise of +12.24% [1] - The company posted revenues of $0.89 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 86.45%, compared to year-ago revenues of $0.52 million [2] - Over the last four quarters, CRISPR Therapeutics has surpassed consensus EPS estimates three times [2] Group 2: Stock Performance and Outlook - CRISPR Therapeutics shares have increased approximately 42.5% since the beginning of the year, significantly outperforming the S&P 500's gain of 6.1% [3] - The company's earnings outlook, including current consensus earnings expectations for upcoming quarters, will be crucial for investors [4] - The current consensus EPS estimate for the coming quarter is -$1.35 on revenues of $8.89 million, and -$5.61 on revenues of $41.42 million for the current fiscal year [7] Group 3: Industry Context - The Medical - Biomedical and Genetics industry, to which CRISPR Therapeutics belongs, is currently ranked in the bottom 43% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact investor decisions [5] - The unfavorable estimate revisions trend prior to the earnings release resulted in a Zacks Rank 5 (Strong Sell) for CRISPR Therapeutics, suggesting expected underperformance in the near future [6]

Hims & Hers Health, Inc. (HIMS) came out with quarterly earnings of $0.17 per share, missing the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.06 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -5.56%. A quarter ago, it was expected that this company would post earnings of $0.12 per share when it actually produced earnings of $0.2, delivering a surprise of +66.67%.Over the last four quarters, the ...

What's Next for Transocean? Transocean (RIG) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to a loss of $0.15 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +100.00%. A quarter ago, it was expected that this offshore oil and gas drilling contractor would post a loss of $0.12 per share when it actually produced a loss of $0.1, delivering a surprise of +1 ...